Licensing status

Publication and contact information


Chronic lymphocytic leukemia (CLL)

Yippee-like 5 (YPEL5); protein phosphatase 1 catalytic subunit b-isozyme (PPP1CB)

Patient sample and cell culture studies have identified a YPEL5-PPP1CB fusion transcript that could be a marker or therapeutic target in the disease. The YPEL5-PPP1CB fusion transcript was detected in 97 of 103 samples from patients with CLL but not in any healthy controls. In vitro, the fusion transcript produced a truncated PPP1CB protein with less phosphatase activity than the wild-type protein. In cultured CLL cells, small hairpin RNA against PPP1CB increased cell proliferation compared with control shRNA. Next steps include determining when and how this fusion transcript is produced in patients with CLL.

SciBX 6(8); doi:10.1038/scibx.2013.191
Published online Feb. 28, 2013

Patent and licensing status undisclosed

Velusamy, T. et al. Proc. Natl. Acad. Sci. USA; published online Feb. 4, 2013;
Contact: Kojo S.J. Elenitoba-Johnson, University of Michigan, Ann Arbor, Mich.

Contact: Arul M. Chinnaiyan, same affiliation as above